Irofulven
- Generic Name
- Irofulven
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18O3
- CAS Number
- 158440-71-2
- Unique Ingredient Identifier
- 6B799IH05A
- Background
A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track” status by the U.S. Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers.
...
- Indication
Investigated for use/treatment in brain cancer, breast cancer, endometrial cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, pediatric indications, prostate cancer, and sarcoma.
- Associated Conditions
- -
- Associated Therapies
- -
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
- Conditions
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT03643107
- Locations
- 🇩🇰
Rigshospitalet, Dept. Of Oncology, Copenhagen, Denmark
Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
- First Posted Date
- 2006-09-11
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT00374660
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT00124566
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 36
- Registration Number
- NCT00003666
- Locations
- 🇺🇸
University of California San Diego Cancer Center, La Jolla, California, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer
- Conditions
- First Posted Date
- 2004-08-26
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003390
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer
- Conditions
- First Posted Date
- 2004-08-09
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005070
Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer
- Conditions
- First Posted Date
- 2004-08-04
- Last Posted Date
- 2012-08-09
- Target Recruit Count
- 3
- Registration Number
- NCT00003760
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Brooke Army Medical Center, Fort Sam Houston, Texas, United States
🇺🇸San Antonio Cancer Institute, San Antonio, Texas, United States
Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer
- First Posted Date
- 2004-08-04
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT00003786
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Michiana Hematology/Oncology P.C., South Bend, Indiana, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Irofulven in Treating Patients With Stage IV Melanoma
- Conditions
- First Posted Date
- 2004-06-21
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT00005968
- Locations
- 🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
🇺🇸University of Colorado Cancer Center, Denver, Colorado, United States
6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00003997
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.